Inhibikase Therapeutics

12/13/2024

Risvodetinib is a developmental disease-modifying therapy that has the potential to halt progression and reverse the functional loss arising from Parkinson’s disease while simultaneously reducing or clearing the toxic form of alpha-synuclein believed to be the cause of PD. Learn more:

Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), is a potent, selective small-molecule designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halti...

12/10/2024

Pulmonary arterial hypertension (PAH) has a 61% 5-year survival rate, indicating the poor prognosis of patients afflicted with this rare disease. Inhibikase is dedicated to developing IkT-001Pro, a potential disease-modifying treatment, to provide new hope to people suffering with PAH. Learn more:

Pulmonary Arterial Hypertension, or PAH, is a rare disease of the pulmonary, or lung, microvasculature, characterized by hypertension that affects the functioning of the right-side of the heart, the side of the heart that sends and receives blood to and from the lungs. PAH mostly afflicts women betw...

12/05/2024

Our prodrug technology platform enables potentially greater control over the non-hematological side effects common to kinase inhibitor therapies, such as nausea or diarrhea, and it may improve drug delivery into the target tissue. Learn more:

We target a key event, the point at which degeneration is initiated inside the affected neurons, which we believe initiates the disease.

12/02/2024

Inhibikase's drug development programs focus on halting and reversing the effects of neurodegenerative diseases inside and outside of the brain. See our pipeline here:

Risvodetinib (IkT-148009) is our lead product candidate to treat Parkinson’s and related diseases. Emerging from our RAMP™ discovery engine, Risvodetinib (IkT-148009) is currently completing Phase 2 studies in untreated Parkinson’s patients evaluating the safety, tolerability and efficacy of o...

11/26/2024

During this November join us in highlighting pulmonary arterial hypertension (PAH), a serious condition which is a subset of pulmonary hypertension that affects the lungs and heart. Learn more about PAH from Pulmonary Hypertension Association here: https://bit.ly/3ZiHDLJ

About Pulmonary Hypertension Not all pulmonary hypertension (PH) is the same. PH is a general term used to describe high blood pressure in the lungs from any cause. There are five different groups of PH based on different causes. Sometimes, people refer to the five types of PH as WHO Groups because....

11/21/2024

November is ! Pulmonary arterial hypertension (PAH), a subset of PH, is a serious, progressive disease of the lungs, primarily affecting small pulmonary arterioles which can lead to heart failure and death. Learn more about PAH here:

Understand what PAH is, symptoms and risk factors and how to manage the condition.

11/14/2024

Our CEO Dr. Milton Werner comments on Inhibikae's third quarter financial results and recent activity. For more details, visit: https://bit.ly/3UQpXEo

11/14/2024

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into…...

11/11/2024

Inhibikase is dedicated to developing new treatment options for Parkinson's disease that have the potential to halt disease progression and reverse functional loss. Learn more about our work here: https://bit.ly/3rOPDkl

11/06/2024

The active ingredient in Inhibikase's IkT-001Pro, imatinib, has previously been shown to be disease-modifying for Pulmonary Arterial Hypertension (PAH). Learn how IkT-001Pro has the potential to offer a more favorable safety and tolerability profile compared to imatinib for PAH:

Pulmonary Arterial Hypertension, or PAH, is a rare disease of the pulmonary, or lung, microvasculature, characterized by hypertension that affects the functioning of the right-side of the heart, the side of the heart that sends and receives blood to and from the lungs. PAH mostly afflicts women betw...

11/01/2024

Pulmonary arterial hypertension (PAH) is a serious condition that can be life-threatening in which the small blood vessels in your lungs become narrow and blood can’t flow through your lungs as well as it should. Learn more here:

Pulmonary arterial hypertension (PAH) is a narrowing of the small blood vessels in your lungs. Causes include connective tissue diseases and genetic mutations.

10/29/2024

Currently, all marketed therapeutic approaches to treat Parkinson’s help manage the symptoms of the disease, but do not slow or stop the disease’s relentless progression. See how inhibikase is working to target the underlying biological mechanism resulting in Parkinson’s disease here:

Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), is a potent, selective small-molecule designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halti...

10/24/2024

Inhibikase is working to provide meaningful treatment options for patients with Parkinson’s Disease that could change the course of the disease in the body. Learn about risvodetinib, our innovative small-molecule kinase inhibitor, here:

Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), is a potent, selective small-molecule designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halti...

10/21/2024

Roberto Bellini, former Chief Executive of BELLUS Health and current Managing Partner of BSQUARED Capital, comments on his appointment as Independent Chairperson of the Inhibikase Board. Learn more here: https://bit.ly/3YhKxym

10/21/2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal…...

10/14/2024

IkT-001Pro's potential improvement in the side effect profile of imatinib coupled with changes in the treatment paradigm for Pulmonary Arterial Hypertension (PAH) standard of care suggests IkT-001Pro could be a successful treatment for this rare, but rapidly fatal disease. Learn more: https://bit.ly/3W60TKI

Pulmonary Arterial Hypertension, or PAH, is a rare disease of the pulmonary, or lung, microvasculature, characterized by hypertension that affects the functioning of the right-side of the heart, the side of the heart that sends and receives blood to and from the lungs. PAH mostly afflicts women betw...

10/09/2024

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and…...

10/04/2024

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused when the tiny arteries in your lungs become thickened and narrowed. Learn more about this disease from the American Lung Association:

Pulmonary Arterial Hypertension (PAH) is a specific type of pulmonary hypertension that is caused when the tiny arteries in your lung become thickened and na...